Literature DB >> 24591489

PET/CT imaging of chemokine receptor CCR5 in vascular injury model using targeted nanoparticle.

Hannah P Luehmann1, Eric D Pressly, Lisa Detering, Cynthia Wang, Richard Pierce, Pamela K Woodard, Robert J Gropler, Craig J Hawker, Yongjian Liu.   

Abstract

UNLABELLED: Inflammation plays important roles at all stages of atherosclerosis. Chemokine systems have major effects on the initiation and progression of atherosclerosis by controlling the trafficking of inflammatory cells in vivo through interaction with their receptors. Chemokine receptor 5 (CCR5) has been reported to be an active participant in the late stage of atherosclerosis and has the potential as a prognostic biomarker for plaque stability. However, its diagnostic potential has not yet been explored. The purpose of this study was to develop a targeted nanoparticle for sensitive and specific PET/CT imaging of the CCR5 receptor in an apolipoprotein E knock-out (ApoE(-/-)) mouse vascular injury model.
METHODS: The D-Ala1-peptide T-amide (DAPTA) peptide was selected as a targeting ligand for the CCR5 receptor. Through controlled conjugation and polymerization, a biocompatible poly(methyl methacrylate)-core/polyethylene glycol-shell amphiphilic comblike nanoparticle was prepared and labeled with (64)Cu for CCR5 imaging in the ApoE(-/-) wire-injury model. Immunohistochemistry, histology, and real-time reverse transcription polymerase chain reaction (RT-PCR) were performed to assess the disease progression and upregulation of CCR5 receptor.
RESULTS: The (64)Cu-DOTA-DAPTA tracer showed specific PET imaging of CCR5 in the ApoE(-/-) mice. The targeted (64)Cu-DOTA-DAPTA-comb nanoparticles showed extended blood signal and optimized biodistribution. The tracer uptake analysis showed significantly higher accumulations at the injury lesions than those acquired from the sham-operated sites. The competitive PET receptor blocking studies confirmed the CCR5 receptor-specific uptake. The assessment of (64)Cu-DOTA-DAPTA-comb in C57BL/6 mice and (64)Cu-DOTA-comb in ApoE(-/-) mice verified low nonspecific nanoparticle uptake. Histology, immunohistochemistry, and RT-PCR analyses verified the upregulation of CCR5 in the progressive atherosclerosis model.
CONCLUSION: This work provides a nanoplatform for sensitive and specific detection of CCR5's physiologic functions in an animal atherosclerosis model.

Entities:  

Keywords:  CCR5; PET/CT; atherosclerosis; chemokine receptor; nanoparticles

Mesh:

Substances:

Year:  2014        PMID: 24591489      PMCID: PMC4255944          DOI: 10.2967/jnumed.113.132001

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  33 in total

1.  Pathways for internalization and recycling of the chemokine receptor CCR5.

Authors:  Anja Mueller; Eamonn Kelly; Philip G Strange
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques.

Authors:  Frank Tacke; David Alvarez; Theodore J Kaplan; Claudia Jakubzick; Rainer Spanbroek; Jaime Llodra; Alexandre Garin; Jianhua Liu; Matthias Mack; Nico van Rooijen; Sergio A Lira; Andreas J Habenicht; Gwendalyn J Randolph
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

Review 3.  The many roles of chemokines and chemokine receptors in inflammation.

Authors:  Israel F Charo; Richard M Ransohoff
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

4.  Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo.

Authors:  Jun-o Deguchi; Masanori Aikawa; Ching-Hsuan Tung; Elena Aikawa; Dong-Eog Kim; Vasilis Ntziachristos; Ralph Weissleder; Peter Libby
Journal:  Circulation       Date:  2006-06-26       Impact factor: 29.690

5.  Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA).

Authors:  Maria T Polianova; Francis W Ruscetti; Candace B Pert; Michael R Ruff
Journal:  Antiviral Res       Date:  2005-08       Impact factor: 5.970

6.  Chemokine receptor 5 antagonist D-Ala-peptide T-amide reduces microglia and astrocyte activation within the hippocampus in a neuroinflammatory rat model of Alzheimer's disease.

Authors:  S Rosi; C B Pert; M R Ruff; K McGann-Gramling; G L Wenk
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

7.  In vivo molecular imaging of atherosclerotic lesions in ApoE-/- mice using VCAM-1-specific, 99mTc-labeled peptidic sequences.

Authors:  Julien Dimastromatteo; Alexis Broisat; Pascale Perret; Mitra Ahmadi; Didier Boturyn; Pascal Dumy; Daniel Fagret; Laurent M Riou; Catherine Ghezzi
Journal:  J Nucl Med       Date:  2013-05-29       Impact factor: 10.057

Review 8.  The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics.

Authors:  Christina A Bursill; Keith M Channon; David R Greaves
Journal:  Curr Opin Lipidol       Date:  2004-04       Impact factor: 4.776

9.  Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10.

Authors:  Alma Zernecke; Elisa A Liehn; Ji-Liang Gao; William A Kuziel; Philip M Murphy; Christian Weber
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

Review 10.  Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors.

Authors:  Michael R Ruff; Maria Polianova; Quan-en Yang; Gifford S Leoung; Francis W Ruscetti; Candace B Pert
Journal:  Curr HIV Res       Date:  2003-01       Impact factor: 1.581

View more
  29 in total

1.  Assessment of Targeted Nanoparticle Assemblies for Atherosclerosis Imaging with Positron Emission Tomography and Potential for Clinical Translation.

Authors:  Yongjian Liu; Hannah P Luehmann; Lisa Detering; Eric D Pressly; Alaina J McGrath; Deborah Sultan; Annie Nguyen; Susannah Grathwohl; Monica Shokeen; Mohamed Zayed; Robert J Gropler; Dana Abendschein; Craig J Hawker; Pamela K Woodard
Journal:  ACS Appl Mater Interfaces       Date:  2019-04-19       Impact factor: 9.229

Review 2.  Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery, Part 1: Compositions and Features.

Authors:  John C Stendahl; Albert J Sinusas
Journal:  J Nucl Med       Date:  2015-08-13       Impact factor: 10.057

Review 3.  Emerging risk biomarkers in cardiovascular diseases and disorders.

Authors:  Ravi Kant Upadhyay
Journal:  J Lipids       Date:  2015-04-08

Review 4.  Recent advances in the preparation and application of multifunctional iron oxide and liposome-based nanosystems for multimodal diagnosis and therapy.

Authors:  Marzia Marciello; Juan Pellico; Irene Fernandez-Barahona; Fernando Herranz; Jesus Ruiz-Cabello; Marco Filice
Journal:  Interface Focus       Date:  2016-12-06       Impact factor: 3.906

Review 5.  Molecular imaging of plaque vulnerability.

Authors:  Sina Tavakoli; Aseem Vashist; Mehran M Sadeghi
Journal:  J Nucl Cardiol       Date:  2014-08-15       Impact factor: 5.952

Review 6.  Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery, Part 2: Radiolabeled Probes.

Authors:  John C Stendahl; Albert J Sinusas
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

7.  Radio-nanomaterials for biomedical applications: state of the art.

Authors:  Weifei Lu; Hao Hong; Weibo Cai
Journal:  Eur J Nanomed       Date:  2016-02-06

8.  Chemokine receptors: Key for molecular imaging of inflammation in atherosclerosis.

Authors:  Yongjian Liu; Pamela K Woodard
Journal:  J Nucl Cardiol       Date:  2018-03-07       Impact factor: 5.952

Review 9.  PET Assessment of Immune Cell Activity and Therapeutic Monitoring Following Myocardial Infarction.

Authors:  James T Thackeray
Journal:  Curr Cardiol Rep       Date:  2018-03-06       Impact factor: 2.931

Review 10.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.